Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia

Systematic Study of Post Herapin Lipoprotein Lipase Activity and Lipoprotein Remodelling in Multifactorial Chylomicronemia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02933138

Enrollment

Registered

2016-10-14

Start date

2010-07-31

Completion date

2015-03-31

Last updated

2016-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipoproteinemia

Keywords

Lipoprotein Lipase, Hypertriglyceridemia, Triglycerides, Lipolysis, Multifactorial Chylomicronemia

Brief summary

Detailed description

Purpose: The mechanism of most of the multifactorial chylomicronemia (MCM) remains elusive. In order to decipher the mechanisms involved in the occurrence of this disease, plasma TG lipolysis characteristics will be monitored for 60 minutes after heparin injection instead of the 10 minutes gold standard, in a large group of genotyped MCM patients. Method: LPL, APOC2, APOA5, GPIHB1and APOE genotypes will be determined for each patient. Basal lipid profiles including Apo B, CII, CIII, and lipoprotein lipase (LPL) concentration will be measured in 62 MCM patients, in addition to LPL activity (PHLA) T0, T10 T30 T60 minutes, Assessment of TG chylomicron decrease Study of lipoprotein remodelling by agarose gel electrophoresis. Hypothesis To confirm the preliminary finding of high LPL activity in multifactorial chylomicronemia To explore the interest of a longer assessment of LPL activity following heparin injection. To establish if specific phenotypes could be identified among MCM patient supporting the hypothesis of different mechanisms involved (ie overproduction or defect in hepatic clearance)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patient with a documented history of MCM (Plasma TG concentration (TG) \> 15 mmol/l or familial history of hypertriglyceridemia with TG \>10 mmol/l) * no contraindication for a single heparin injection for ex vivo LPL activity assessment

Exclusion criteria

* patients carriers of homozygous or compound heterozygous mutations on LPL, GPIHBP1, APOA5, APOC2 or APOE genes

Design outcomes

Primary

Measure	Time frame
Lipoprotein Lipase concentration	60 minutes after heparin injection

Secondary

Measure	Time frame
Basal lipid profiles	maximum 60 min before heparin injection
Lipoprotein electrophoresis	maximum 60 minutes after heparin injection
Total triglycerides decrease	maximum 60 minutes after heparin injection

Outcome results